116 related articles for article (PubMed ID: 3573809)
21. The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus.
Boere WA; Benaissa-Trouw BJ; Harmsen T; Erich T; Kraaijeveld CA; Snippe H
Immunology; 1986 Aug; 58(4):553-9. PubMed ID: 3015781
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of antibody conjugates with cobra venom factor using heterobifunctional cross-linking reagents.
Vogel CW
Targeted Diagn Ther; 1988; 1():191-224. PubMed ID: 2979056
[No Abstract] [Full Text] [Related]
23. The effect of cobra venom factor on alternative pathway hemolytic activity in mice.
Joiner KA; Hawiger A; Gelfand JA
Immunol Commun; 1980; 9(3):277-81. PubMed ID: 7399569
[TBL] [Abstract][Full Text] [Related]
24. Role of antibody-independent complement activation in rejection of porcine bone marrow cells in mice.
Yang YG; Chen AM; Sergio JJ; Zhou Y; Sykes M
Transplantation; 2000 Jan; 69(1):163-5. PubMed ID: 10653396
[TBL] [Abstract][Full Text] [Related]
25. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
26. Cobra venom factor stimulates anti-alpha-galactose antibody production in baboons. Implications for pig-to-human xenotransplantation.
Taniguchi S; Kobayashi T; Neethling FA; Ye Y; Niekrasz M; White DJ; Cooper DK
Transplantation; 1996 Sep; 62(5):678-81. PubMed ID: 8830836
[TBL] [Abstract][Full Text] [Related]
27. Opportunities for new therapies based on the natural regulators of complement activation.
Brook E; Herbert AP; Jenkins HT; Soares DC; Barlow PN
Ann N Y Acad Sci; 2005 Nov; 1056():176-88. PubMed ID: 16387686
[TBL] [Abstract][Full Text] [Related]
28. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Soliakov LS; Zinchenko AA
Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
[TBL] [Abstract][Full Text] [Related]
29. In vivo studies with covalent conjugates of cobra venom factor and monoclonal antibodies to human tumors.
Vogel CW; Wilkie SD; Morgan AC
Haematol Blood Transfus; 1985; 29():514-7. PubMed ID: 4029740
[No Abstract] [Full Text] [Related]
30. Structure and function of cobra venom factor, the complement-activating protein in cobra venom.
Vogel CW; Bredehorst R; Fritzinger DC; Grunwald T; Ziegelmüller P; Kock MA
Adv Exp Med Biol; 1996; 391():97-114. PubMed ID: 8726051
[No Abstract] [Full Text] [Related]
31. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
32. Evidence of IgG-mediated enhancement of the antibody response in vivo without complement activation via the classical pathway.
Wiersma EJ; Nose M; Heyman B
Eur J Immunol; 1990 Dec; 20(12):2585-9. PubMed ID: 2269326
[TBL] [Abstract][Full Text] [Related]
33. Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways.
Bindon CI; Hale G; Hughes-Jones N; Gorick B; Waldmann H
Mol Immunol; 1987 Jun; 24(6):587-94. PubMed ID: 2958690
[TBL] [Abstract][Full Text] [Related]
34. The role of complement activation in tumour necrosis factor-induced lethal hepatitis.
Libert C; Wielockx B; Grijalba B; Van Molle W; Kremmer E; Colten HR; Fiers W; Brouckaert P
Cytokine; 1999 Aug; 11(8):617-25. PubMed ID: 10433810
[TBL] [Abstract][Full Text] [Related]
35. Induction of human complement activation without cytolysis by mouse monoclonal antibodies to human leukocyte antigens.
Sugita K; Majdic O; Stockinger H; Holter W; Burger R; Knapp W
Transplantation; 1987 Apr; 43(4):570-4. PubMed ID: 3576673
[TBL] [Abstract][Full Text] [Related]
36. Statin drugs do not affect serum complement activation in vitro.
Lappegård KT; Hvassing T; Mollnes TE
Scand J Immunol; 2004; 60(1-2):178-83. PubMed ID: 15238087
[TBL] [Abstract][Full Text] [Related]
37. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.
Robinson WE; Montefiori DC; Mitchell WM
Lancet; 1988 Apr; 1(8589):790-4. PubMed ID: 2895317
[TBL] [Abstract][Full Text] [Related]
38. Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.
Cooper PD; Sim RB
Int J Cancer; 1984 May; 33(5):683-7. PubMed ID: 6724743
[TBL] [Abstract][Full Text] [Related]
39. Quantification of large C3 fragments as an index of complement activation in mice. II. In vivo studies.
Lulé J; Fournié GJ; Conté JJ
Complement; 1984; 1(2):103-7. PubMed ID: 6399880
[TBL] [Abstract][Full Text] [Related]
40. Activation of the alternative complement pathway by unidentified substances in human glomerulonephritis.
Schena FP; Pertosa G; Vox E; Bonomo L
Nephron; 1981; 27(1):9-14. PubMed ID: 6908651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
